logo
Plus   Neg
Share
Email

Gilead: Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta

Biopharmaceutical company Gilead Sciences Inc. (GILD) announced Sunday that its unit Kite revealed long-term follow-up data from the pivotal ZUMA-1 study of Yescarta (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma.

Yescarta is the first chimeric antigen receptor T or CAR T cell therapy to be approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma or DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Yescarta is not indicated for patients with primary central nervous system lymphoma.

Kite, focused on chimeric antigen receptor and T cell receptor engineered cell therapies, noted that with a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission.

Detailed results were presented at the Annual Meeting of the American Society of Hematology in Atlanta and published in The New England Journal of Medicine.

Sattva Neelapu, ZUMA-1 Co-Lead Investigator, said, "As observed in the SCHOLAR-1 study, treatment options for patients with refractory large B-cell lymphoma have yielded a median overall survival of just six months, with fewer than ten percent of patients achieving complete remission. The durability of response seen with Yescarta in this long-term follow-up reinforces the major advance that CAR T therapy represents for these patients."

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon.com Inc.'s (AMZN) Chief Executive Jeff Bezos has told the company's employees said that the tech giant is not too big to fail, according to media reports. Shares of Nordstrom Inc. (JWN) slipped 10 percent in extended hours on Thursday after the department store chain's full-year revenue outlook fell short of Street estimates. Seattle-based Nordstrom's third-quarter profit dropped to $67 million or $0.39 per share from $114 million or $0.67 per share... Shares of Nvidia Corp. (NVDA) plunged 16% in extended session on Thursday after chip designer's third-quarter revenues and fourth quarter outlook fell short of Wall Street estimates. Santa Clara, California-based Nvidia's third-quarter profit surged to $1.23 billion or $1.97 per share from $838 million...
Follow RTT